163 related articles for article (PubMed ID: 34326838)
1. Response: Commentary: An
Mishto M; Rodriguez-Hernandez G; Neefjes J; Urlaub H; Liepe J
Front Immunol; 2021; 12():679836. PubMed ID: 34326838
[No Abstract] [Full Text] [Related]
2. Commentary: An
Beer I
Front Immunol; 2021; 12():523906. PubMed ID: 34326832
[No Abstract] [Full Text] [Related]
3. An
Mishto M; Mansurkhodzhaev A; Ying G; Bitra A; Cordfunke RA; Henze S; Paul D; Sidney J; Urlaub H; Neefjes J; Sette A; Zajonc DM; Liepe J
Front Immunol; 2019; 10():2572. PubMed ID: 31803176
[TBL] [Abstract][Full Text] [Related]
4. In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.
Willimsky G; Beier C; Immisch L; Papafotiou G; Scheuplein V; Goede A; Holzhütter HG; Blankenstein T; Kloetzel PM
Elife; 2021 Apr; 10():. PubMed ID: 33875134
[TBL] [Abstract][Full Text] [Related]
5. [Preclinical study of T cell receptor specifically reactive with
Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
[TBL] [Abstract][Full Text] [Related]
6. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
8. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
[TBL] [Abstract][Full Text] [Related]
9. Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.
Bai P; Zhou Q; Wei P; Bai H; Chan SK; Kappler JW; Marrack P; Yin L
Sci China Life Sci; 2021 Dec; 64(12):2144-2152. PubMed ID: 33740187
[TBL] [Abstract][Full Text] [Related]
10. Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS.
Ramalingam PS; Arumugam S
Med Oncol; 2023 Aug; 40(10):283. PubMed ID: 37644143
[TBL] [Abstract][Full Text] [Related]
11. Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.
Fossum B; Gedde-Dahl T; Hansen T; Eriksen JA; Thorsby E; Gaudernack G
Eur J Immunol; 1993 Oct; 23(10):2687-91. PubMed ID: 7691613
[TBL] [Abstract][Full Text] [Related]
12. Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Wright KM; DiNapoli SR; Miller MS; Aitana Azurmendi P; Zhao X; Yu Z; Chakrabarti M; Shi W; Douglass J; Hwang MS; Hsiue EH; Mog BJ; Pearlman AH; Paul S; Konig MF; Pardoll DM; Bettegowda C; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S; Gabelli SB
Nat Commun; 2023 Aug; 14(1):5063. PubMed ID: 37604828
[TBL] [Abstract][Full Text] [Related]
13. In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant
Ng AWR; Tan PJ; Hoo WPY; Liew DS; Teo MYM; Siak PY; Ng SM; Tan EW; Abdul Rahim R; Lim RLH; Song AAL; In LLA
PeerJ; 2018; 6():e5056. PubMed ID: 30042874
[TBL] [Abstract][Full Text] [Related]
14. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.
Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW
Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088
[TBL] [Abstract][Full Text] [Related]
15. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G
Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844
[TBL] [Abstract][Full Text] [Related]
16. Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma.
Frøsig TM
Dan Med J; 2015 Aug; 62(8):B5144. PubMed ID: 26239596
[TBL] [Abstract][Full Text] [Related]
17. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
18. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
Wang QJ; Yu Z; Griffith K; Hanada K; Restifo NP; Yang JC
Cancer Immunol Res; 2016 Mar; 4(3):204-14. PubMed ID: 26701267
[TBL] [Abstract][Full Text] [Related]
19. KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer.
Pan LN; Ma YF; Li Z; Hu JA; Xu ZH
Cell Biol Int; 2021 Apr; 45(4):795-803. PubMed ID: 33325140
[TBL] [Abstract][Full Text] [Related]
20. CD8(+) T cells of Listeria monocytogenes-infected mice recognize both linear and spliced proteasome products.
Platteel AC; Mishto M; Textoris-Taube K; Keller C; Liepe J; Busch DH; Kloetzel PM; Sijts AJ
Eur J Immunol; 2016 May; 46(5):1109-18. PubMed ID: 26909514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
